euro adhoc: november AG
Restructuring & Recapitalisations
Capital Increase
entered in commercial register
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
20.11.2007
Erlangen, 20. November 2007. According to the decision made at the last annual shareholder´s meeting on May 22nd 2007, november AG has successfully completed the capital increase against contribution in kind by contributing the companies IBL Gesellschaft für Immunchemie und Immunbiologie mbH (Hamburg) and PROGEN Biotechnik GmbH, (Heidelberg). Yesterday, these measures were entered in the commercial register by the competent court. The capital stock has now been increased by EUR 10.287.356,00 from EUR 3.754.160,00 to EUR 14.041.516,00.
end of announcement euro adhoc 20.11.2007 11:38:53
Further inquiry note:
Marcus Weichert
Leitung PR/IR
Telefon: +49(0)9131 75088 868
E-Mail: weichert@november.de
Branche: Biotechnology
ISIN: DE0006762909
WKN: 676290
Index: CDAX, Technologie All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade